<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04495881</url>
  </required_header>
  <id_info>
    <org_study_id>2020-DM-Sitagliptin</org_study_id>
    <nct_id>NCT04495881</nct_id>
  </id_info>
  <brief_title>Sitagliptin for the Treatment of Type 2 Diabetes</brief_title>
  <official_title>Effectiveness of Sitagliptin for the Treatment of Newly Diagnosed Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients newly diagnosed with T2D will be recruited and will receive sitagliptin treatment&#xD;
      for 3 months. The gut microbiome of the participants before and after the treatment and the&#xD;
      effectiveness of sitagliptin treatment on type 2 diabetes will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dipeptidyl peptidase-4 inhibitor sitagliptin is a classic anti-diabetic drug(1) and is&#xD;
      widely applied to both scientific research and clinical trial(2-6). This clinical trial aims&#xD;
      to study the effectiveness of sitagliptin treatment in T2D patients and related change of gut&#xD;
      microbiome. 50 Patients newly diagnosed with T2D will be recruited. With patient's informed&#xD;
      consent, patient-related vital signs (such as age, height, weight, body mass index),&#xD;
      laboratory indicators (including glycated hemoglobin, glycated albumin, low-density&#xD;
      lipoprotein, total cholesterol, triglycerides), fasting blood glucose, insulin levels and&#xD;
      Insulin resistance index (HOMA-IR)(7) will be recorded and analyzed. The feces of the&#xD;
      patients will be collected to analyze the gut microbiome. All of the patients will receive&#xD;
      the sitagliptin treatment for 3 months. The gut microbiome of the patients and the&#xD;
      effectiveness of sitagliptin treatment on diabetes will be evaluated at indicated times&#xD;
      during follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c change</measure>
    <time_frame>Changes in HbA1c from baseline at 1 month and 3 months during follow-up</time_frame>
    <description>Changes in HbA1c from baseline at 1 month and 3 months during follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting blood glucose change</measure>
    <time_frame>Changes in fasting blood glucose from baseline at 1 month and 3 months during follow-up</time_frame>
    <description>Changes in fasting blood glucose from baseline at 1 month and 3 months during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR change</measure>
    <time_frame>Changes in HOMA-IR from baseline at 1 month and 3 months during follow-up</time_frame>
    <description>Changes in HOMA-IR from baseline at 1 month and 3 months during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated Albumin（GSA）change</measure>
    <time_frame>Changes in Glycated Albumin from baseline at 1 month and 3 months during follow-up</time_frame>
    <description>Changes in Glycated Albumin from baseline at 1 month and 3 months during follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sitagliptin 100mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin 100mg</intervention_name>
    <description>Sitagliptin 100mg Qd</description>
    <arm_group_label>sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18-65 years old newly diagnosed with type 2 diabetes&#xD;
&#xD;
          -  HbA1c ≥ 7%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The positive of diabetes antibodies&#xD;
&#xD;
          -  Anti-diabetic drugs therapy before participation&#xD;
&#xD;
          -  Pancreatitis&#xD;
&#xD;
          -  Coronary artery disease&#xD;
&#xD;
          -  Liver function impairment&#xD;
&#xD;
          -  Renal function impairment&#xD;
&#xD;
          -  History of intestinal surgery&#xD;
&#xD;
          -  Chronic hypoxic diseases (emphysema and cor pulmonale)&#xD;
&#xD;
          -  Infectious disease&#xD;
&#xD;
          -  Hematological disease&#xD;
&#xD;
          -  Systemic inflammatory disease&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Ingesting agents known to influence glucose or lipid metabolism;&#xD;
&#xD;
          -  Any antibiotics or probiotics in the past three months prior to the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guang Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jia Liu, MD</last_name>
    <phone>010-85231710</phone>
    <email>liujia0116@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan Duan, MD</last_name>
    <phone>010-85231711</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia liu, MD</last_name>
      <phone>861085231710</phone>
      <email>liujia0116@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2020</study_first_posted>
  <last_update_submitted>August 1, 2020</last_update_submitted>
  <last_update_submitted_qc>August 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Guang Wang</investigator_full_name>
    <investigator_title>Professor and Director, Department of Endocrinology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

